A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy, safety and tolerability of once monthly
administration of subcutaneous Mircera for the maintenance of hemoglobin levels in dialysis
patients with chronic renal anemia. Patients will receive subcutaneous Mircera at a starting
dose of 120, 200 or 360 micrograms every 4 weeks, calculated from the last weekly dose of
epoetin or darbepoetin alfa previously administered. Subsequent doses will be adjusted to
maintain hemoglobin levels within the target range. Treatment duration is 56 weeks, and the
target sample size is 200 individuals.